Nasopharyngeal carcinoma
Conditions
Interventions
1:Fasting oral Anlotinib Hydrochloride Capsules 1 capsule daily+GP induced chemotherapy+IMRT concurrent chemotherapy
2:GP induced chemotherapy+IMRT concurrent chemotherapy
Sponsors
Wuzhou Red Cross Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Gender is not limited, aged 18 to 70 years; 2) Pathologically confirmed non-differentiated non-keratinized carcinoma of the nasopharynx and differentiated non-keratinized carcinoma; 3) Patients who meet the III-IVA in the UICC/AJCC 8th Edition/China 2017 edition; 4) Karsten score = 70 points; 5) There are MRI and other imaging data of the nasopharynx before treatment, and there are tumor lesions that can be measured; 6) This treatment must be the first treatment; 7) Expected survival expectation not less than 6 months; 8) Patients enrolled must also meet the following clinical laboratory criteria: hemoglobin, white blood cells, platelets, and liver and kidney function indicators are within 1.25 times the upper and lower limits of normal values. 9) Can understand the study and have signed an informed consent form; 10) There are follow-up conditions.
Exclusion criteria
Exclusion criteria: 1) Previously suffered from other malignant tumors (except for stage I non-melanoma skin cancer or cervical carcinoma in situ). 2) Those who received the current internationally recognized systemic treatment for effective anti-tumor treatments before enrollment. 3) Pregnant or lactating women, women of childbearing age are not contraceptive. 4) Those who are receiving other drug trials. 5) Those with severe comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, mental illness and uncontrollable diabetes. 6) Those who do not have regular follow-up conditions. 7) Cannot accept MRI inspectors. 8) Those who cannot meet the prescription dosage requirements. 9) Those with a significant tendency to major bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;Adverse reactions;1, 3 year survival rate; | — |
Countries
China
Contacts
Public ContactJinhui Liang
Wuzhou Red Cross Hospital
Outcome results
None listed